general
Archived signal
Amplia gets nod for new cancer drug trial ahead of US push
Amplia Therapeutics has received ethics approval for its ACCENT-Mini pancreatic cancer trial, paving the way to test daily doses of its narmafotinib drug alongside chemotherapy.
Reported by Sydney Morning Herald
Read the complete report at Sydney Morning Herald ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
4 reports · 4 sources
Sydney Morning HeraldAmplia gets nod for new cancer drug trial ahead of US pushThe AgeAmplia gets nod for new cancer drug trial ahead of US pushThe AgeAmplia gets nod for new cancer drug trial ahead of US pushSydney Morning HeraldAmplia gets nod for new cancer drug trial ahead of US push7 recorded states
Signal first indexedP1 · 68% quality · 1 source
Corroboration 1→2 sources · quality 68→72P1 · 72% quality · 2 sources
Quality 72→76P1 · 76% quality · 2 sources
Quality 76→80P1 · 80% quality · 2 sources
Quality 80→84P1 · 84% quality · 2 sources
Corroboration 2→3 sources · quality 84→92P1 · 92% quality · 3 sources
Corroboration 3→4 sources · quality 92→99P1 · 99% quality · 4 sources